India · Delayed Price · Currency is INR Verve Therapeutics Statistics
Total Valuation
NSE:CLSEL has a market cap or net worth of INR 14.73 billion. The enterprise value is 15.39 billion.
| Market Cap | 14.73B |
| Enterprise Value | 15.39B |
Important Dates
The last earnings date was Tuesday, August 5, 2025.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | Sep 20, 2024 |
Share Statistics
| Current Share Class | 49.73M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.79% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.52M |
Valuation Ratios
The trailing PE ratio is 14.46.
| PE Ratio | 14.46 |
| Forward PE | n/a |
| PS Ratio | 1.02 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 15.10 |
| EV / Sales | 1.07 |
| EV / EBITDA | 11.11 |
| EV / EBIT | 11.33 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.89 |
| Debt / FCF | n/a |
| Interest Coverage | 14.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.73% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 85.73M |
| Profits Per Employee | 6.07M |
| Employee Count | 168 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:CLSEL has paid 329.71 million in taxes.
| Income Tax | 329.71M |
| Effective Tax Rate | 24.45% |
Stock Price Statistics
The stock price has increased by +34.05% in the last 52 weeks. The beta is 0.31, so NSE:CLSEL's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +34.05% |
| 50-Day Moving Average | 341.52 |
| 200-Day Moving Average | 335.97 |
| Relative Strength Index (RSI) | 28.79 |
| Average Volume (20 Days) | 103,353 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:CLSEL had revenue of INR 14.40 billion and earned 1.02 billion in profits. Earnings per share was 20.69.
| Revenue | 14.40B |
| Gross Profit | 3.36B |
| Operating Income | 1.36B |
| Pretax Income | 1.35B |
| Net Income | 1.02B |
| EBITDA | 1.39B |
| EBIT | 1.36B |
| Earnings Per Share (EPS) | 20.69 |
Balance Sheet
The company has 576.05 million in cash and 1.23 billion in debt, giving a net cash position of -655.58 million.
| Cash & Cash Equivalents | 576.05M |
| Total Debt | 1.23B |
| Net Cash | -655.58M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.33B |
| Book Value Per Share | 147.46 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 23.33%, with operating and profit margins of 9.43% and 7.07%.
| Gross Margin | 23.33% |
| Operating Margin | 9.43% |
| Pretax Margin | 9.36% |
| Profit Margin | 7.07% |
| EBITDA Margin | 9.62% |
| EBIT Margin | 9.43% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.25, which amounts to a dividend yield of 0.72%.
| Dividend Per Share | 2.25 |
| Dividend Yield | 0.72% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 4.79% |
| Shareholder Yield | 5.51% |
| Earnings Yield | 6.92% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |